Skip to main navigation
CareDx
  • COMPANY
    • Management Team
    • Board of Directors
    • Compliance
    • Careers
      • Current Openings
      • Benefits
  • PRODUCTS
    • HeartCare, AlloMap
    • KidneyCare, AlloSure
    • Laboratory Products
    • Ottr
  • INVESTORS
  • CONTACT US

Press Releases

Media Inquiries - media@caredxinc.com
Date Title and Summary Additional Formats
Toggle Summary Jan 25, 2021 CareDx Announces Closing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary Jan 20, 2021 CareDx Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary Jan 19, 2021 CareDx Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary Jan 11, 2021 CareDx Reports Preliminary Fourth Quarter and Full Year 2020 Results
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today
View HTML
Toggle Summary Jan 08, 2021 CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers
Acquisition will build on CareDx’s digital capabilities and continue deepening the moat with transplant centers SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and
View HTML
Toggle Summary Jan 08, 2021 CareDx Transplant Leadership Showcased at ASTS 2021
CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and
View HTML
Toggle Summary Jan 07, 2021 CareDx Announces AlloID and Exclusive Partnership with IDbyDNA
AlloID is a Transplant Patient-Specific Metagenomic Infectious Disease Test Platform, Furthering CareDx’s Innovation in Multi-Modality Surveillance Care SOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Today, CareDx , the leading partner in transplant care, and
View HTML
Toggle Summary Jan 04, 2021 CareDx’s AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance
CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and
View HTML
Toggle Summary Dec 22, 2020 CareDx Celebrates the Long-Awaited Passage of the Immuno Bill
Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and
View HTML
Toggle Summary Dec 01, 2020 CareDx Announces First AlloSure Pediatrics Publication
Center-run study published in Pediatric Transplantation demonstrates the utility of AlloSure for identifying allograft rejection SOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development,
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 286 results

Investor Relations

  • Investor Relations
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Analyst Coverage
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
E-mail Alerts
Downloads
RSS
Print
Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

    ©2004-2017 CareDx, Inc. All Rights Reserved.    CareDx is a registered trademark of CareDx, Inc.

    Privacy & Compliance